Ozempic and Smoking Cessation: Evidence and Considerations

Last reviewed: May 17, 2026

Last updated: May 17, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Current research suggests that GLP-1 receptor agonists like semaglutide may influence smoking behavior through effects on dopamine and reward centers in the brain, though evidence remains preliminary and not conclusive. Most clinical trials have not specifically evaluated smoking cessation as a primary outcome, making definitive claims difficult.

For individuals considering GLP-1 medications while managing tobacco use, understanding the mechanisms and limitations of available evidence is essential. PlexusDx's precision-wellness approach includes genetic insights into reward-pathway sensitivity, which may help support a more informed conversation with your healthcare provider about treatment options.

Dopamine Pathways and GLP-1 Receptor Signaling

GLP-1 receptors exist throughout the brain, including regions involved in reward processing and habit formation. Activation of these receptors may modulate dopamine release and reduce cravings related to addictive behaviors. However, the clinical translation of this mechanism to smoking cessation remains under investigation.

Animal models and preliminary human studies suggest potential effects on reward-seeking behavior, but controlled trials specifically measuring smoking quit rates in GLP-1 users are limited. Current evidence does not support prescribing these medications primarily for smoking cessation outside of a comprehensive treatment plan.

What Clinical Studies Actually Show About GLP-1s and Smoking

Available clinical data on GLP-1 medications and smoking comes primarily from post-hoc analyses of weight-loss and diabetes trials, rather than studies designed to test smoking cessation directly. Some observational reports suggest reduced smoking interest among GLP-1 users, but these findings are not definitive or universally replicated.

Study Type	Key Finding	Limitation
Post-hoc analysis of obesity trials	Some users reported reduced smoking interest	Not designed as primary smoking outcome; selection bias possible
Animal model research	GLP-1 activation reduced nicotine reward-seeking	Does not directly translate to human behavior change
Observational reports	Anecdotal reports of decreased cigarette use	No control group; confounded by weight loss and overall health improvements
Randomized smoking-cessation trials	No specific GLP-1 RCTs published to date	Evidence gap remains; more research needed

Reward Sensitivity and Individual Response Variation

Not all individuals respond identically to GLP-1 medications regarding appetite and reward processing. Genetic variation in dopamine-related pathways and GLP-1 receptor sensitivity may influence how powerfully someone experiences reduced cravings or altered reward-seeking behavior.

Understanding your own genetic predispositions in reward and appetite regulation can inform realistic expectations about whether a GLP-1 medication might contribute to behavioral changes beyond weight loss. This context supports more personalized provider discussions.

Safety, Eligibility, and Provider Guidance on Smoking and GLP-1 Use

GLP-1 medications are not approved by the FDA for smoking cessation and should not be prescribed as standalone quit-smoking treatments. Established smoking-cessation approaches include behavioral support, FDA-approved medications (varenicline, bupropion, nicotine replacement), and counseling—all supported by robust clinical evidence.

If you are taking a GLP-1 medication and also use tobacco, discuss both with your healthcare provider. Your provider can monitor for interactions, ensure your smoking-cessation plan includes evidence-based methods, and assess whether a GLP-1 may support overall health goals. Never adjust smoking habits or medications without medical guidance.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test analyzes predispositions in dopamine-related and reward-pathway genes relevant to GLP-1 function, including GLP1R rs6923761 and MC4R rs17782313 variants. These genetic markers may help provide context for how your brain's reward systems respond to GLP-1 activation, potentially informing how much influence a GLP-1 might have on smoking behavior.

The genetic test does not predict whether you will quit smoking or whether a GLP-1 medication will eliminate cravings—genetics influences predisposition, not destiny. Results should be interpreted with a qualified healthcare provider as one factor among many, including your personal smoking history, motivation, and access to evidence-based cessation support.

If you are considering a compounded GLP-1 medication and want to understand your genetic profile in reward sensitivity, the Precision Peptide Genetic Test ($99 as an add-on, $298 standalone) can support a deeper conversation with your provider about realistic expectations and whether additional smoking-cessation tools might benefit your overall plan.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $279/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.